Indication
Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor deficiency.
Loading your page…
Loading your page…
Angioedemas, Hereditary
Marketing Authorisation Holder: Accord Healthcare S.L.U.
EMA Authorisation: 16/07/2021
INN: icatibant
AI Drug & Interaction Analysis
Free account required
Ask Osler about Icatibant Accord: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.